I base this post on the SURMOUNT-MAINTAIN (https://doi.org/10.1016/ trials) and ATTAIN-MAINTAIN (https://lnkd.in/gQQEHmFc) trials. Both are rigorous and worth reading but what do they actually tell us about the fundamental challenge of maintaining weight loss? Honestly: not as much as some headlines suggest.

Lesson 1: If you need dose X, don’t expect dose X/2 to do the same job

SURMOUNT-MAINTAIN tested whether tirzepatide at maximum tolerated dose (MTD, 10–15 mg) could be reduced to 5 mg and still maintain weight loss. Continued MTD maintained ~97% of initial weight loss, reduced 5 mg maintained ~68%, and placebo ~43%. Predictable dose-response. We would never expect a patient well-controlled on an ACE inhibitor to stay equally controlled on less than half that dose yet obesity pharmacotherapy apparently needs an RCT to confirm this. The maintenance challenge remains: patients need to stay on the dose that works, indefinitely, like any other chronic, relapsing disease.

Lesson 2: Drug A → Drug C ≈ Drug B → Drug C. So why the detour?

In ATTAIN-MAINTAIN, participants who lost weight on tirzepatide (cohort 1) or semaglutide (cohort 2) during SURMOUNT-5 were switched to oral orforglipron. Both cohorts converged at ~95.9 kg at week 52, which was entirely predictable. The endpoint is determined by the maintenance drug, not the induction drug. If a patient will end up on orforglipron long-term, one could arguably start there directly.

The differential weight change during the switch is also entirely predictable. Tirzepatide (dual GIP/GLP-1) → orforglipron (GLP-1 only): ~5 kg gain. Semaglutide → orforglipron: ~1 kg change. Semaglutide and orforglipron share the same receptor target and comparable efficacy, so trivial changes in weight, cardiometabolic outcomes, and GI adverse events is exactly what you’d expect. Tirzepatide’s superior efficacy means switching to a lower-potency agent naturally produces larger changes. No pharmacological surprise here.

What these trials do not solve

Obesity medications work while you take them, at the dose you need. The real-world maintenance barriers: cost, side effects, mismatched expectations…. remain largely unaddressed (https://lnkd.in/gZf8-Dkx and https://lnkd.in/gzRVRy3D). That is the problem still waiting for a solution.

Weight cycling may not be as physiologically harmful as its reputation suggests, but focusing on cycling itself risks distracting from the core issue: obesity as a chronic disease that needs ongoing, structured treatment rather than intermittent “on–off” efforts.

In the article “Is weight cycling clinically harmful?” (https://lnkd.in/dqG_4Gjd), Faidon Magkos and Norbert Stefan review human and animal data and find little robust evidence that weight cycling per se causes progressive fat gain, disproportionate loss of lean mass, or lasting metabolic damage once average adiposity is taken into account. In many studies, apparent harms of weight fluctuation seem driven by ageing, unintentional weight loss due to illness, reverse causality, or longer cumulative exposure to obesity rather than cycling itself. The authors conclude that, compared with lifelong, persistent obesity, repeated intentional weight loss attempts may even confer modest clinical benefits, especially when the final body weight ends up lower than baseline.

From a clinical perspective, the debate about “is weight cycling harmful?” feels slightly beside the point, in the same way we rarely ask whether “blood pressure cycling” is harmful: we treat hypertension and dyslipidemia as chronic conditions and aim for continuous control rather than tolerating repeated relapse. If we handle obesity similarly, our priority becomes durable treatment and long-term support, not whether repeated weight loss attempts might have subtle physiological downsides.

At the same time, this article challenges the narrative that “yo‑yo dieting is worse than doing nothing,” which has been both common and demoralizing for patients. I can grudgingly agree that clarifying the limited evidence for physiological harm from intentional weight cycling may reduce fear and guilt, and lower the barrier to initiating treatment, especially pharmacological therapy that patients might worry about stopping later.

For me, the key message to patients is: intermittent weight loss might be better than persistent, untreated obesity (I am still unsure about psychological consequences), but the real goal is to move from cyclical, short‑term efforts to sustained, chronic‑disease management with appropriate tools, follow‑up, and relapse plans (“what do when….?”) built in from the start.